Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Diffusion Pharmaceuticals
  4. Financial Statements
  5. Income Statement
Diffusion Pharmaceuticals logo
Diffusion Pharmaceuticals DFFN
report update icon

Quarterly report 2026-Q2
added 08-07-2026

Diffusion Pharmaceuticals Income Statement 2025-2010 | DFFN

Annual Income Statement Diffusion Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

 - - 11.7 M 2.91 M 27.5 M 61.4 M 2.82 M 6.94 M 7.97 M 32.7 M 7.82 B 44.6 M 7.94 M 19.5 M 69 M -

Shares

 9.04 M 8.07 M 2.66 M 518 K 2.04 M 53.8 M 6.71 M 3.24 M 830 K 682 K 18.6 M 95.3 K 17.6 K 10 K 10 K 57.7 M

Historical Prices

 - - 4.4 5.61 13.5 57 21.5 110 458 2.26 K 9.3 K 24.8 K 22.5 K 90 K 338 K -

Net Income

 -27 M -16.3 M -2.17 M -5.8 M -24.1 M -14.2 M -11.8 M -18.4 M -1.36 M -18 M - -14.4 M -2.46 M -6.85 M -15.8 M -8.41 M

Revenue

 4.01 M 9.74 M 7.14 M - - - - - - - - - 71.7 K 375 K 570 K -

Cost of Revenue

 - - - - - - - - - - - - - 236 K 2.31 M 210 K

Gross Profit

 - - - - - - - - - - - - 71.7 K 139 K -1.74 M -170 K

Operating Income

 -28.3 M -18.2 M -7.81 M -3.48 M -24.7 M -16 M -11.6 M -19 M -11.3 M -18.4 M -6.41 M -14.6 M -12.8 M -11.8 M -16.4 M -7.64 M

Interest Expense

 -8.33 K -991 - 587 - - - 3 K 100 K 29.7 K 313 K 274 K -228 K 168 K 30.5 K -

EBITDA

 -28.3 M -18.2 M -7.81 M -3.48 M -24.6 M -15.9 M -11.5 M -11.9 M -11.3 M -18.3 M - -7.38 M -6.08 M -6.69 M -14.5 M -7.59 M

Operating Expenses

 32.3 M 28 M 15 M 3.48 M - 16 M 11.6 M 12 M 11.3 M 18.4 M 6 M 7.94 M 6.83 M 6.86 M 12.8 M 7.47 M

General and Administrative Expenses

 10.5 M 9.17 M 6.52 M 2.14 M 7.45 M 6.44 M 4.83 M 6.17 M 6.19 M 11.1 M - 4.76 M 3.08 M 6.83 M 12.8 M 2.17 M

All numbers in USD currency

Quarterly Income Statement Diffusion Pharmaceuticals

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 10.2 M 9.26 M 9.25 M 8.95 M 8.7 M 8.7 M 8.7 M 8.7 M 6.17 M 5.67 M 3.31 M 518 K 518 K 518 K 518 K 2.04 M 2.04 M 2.04 M 2.04 M 2.04 M 1.65 M 64 M 64 M 64 M 64 M 33.5 M 33.5 M 33.5 M 33.5 M 3.38 M 50.6 M 50.5 M 42.1 M 968 K 13.9 M 10.8 M 10.3 M 10.3 M 10.3 M 10.3 M 10 M 8.12 M 18.6 M 18.6 M 18.6 M 18.6 M 18.7 M 12.9 M 5.93 M 5.81 M 5.81 M 5.81 M 5.81 M 891 K 89.7 M 88.2 M 89.1 M 88.2 M 77.5 M 71.2 M -

Net Income

 -6.57 M -7.96 M -7.73 M -6.26 M -4.89 M - -4.75 M -2.32 M -2.51 M - 2.15 M -1.43 M -534 K - -883 K -4.19 M -4.53 M - -12.2 M -3.78 M -4.64 M - -4.44 M -3.13 M -2.56 M - -2.8 M -2.5 M -2.75 M - -6.72 M -2.77 M -3.31 M - 5.1 M 20.4 M -28.6 M - -5.44 M -3.81 M -6.22 M - -1.42 M -1.33 M -1.24 M - -3.45 M -4.46 M -1.38 M - -1.53 M 2.35 M -2.48 M - -3.46 M -1.32 M -291 K - -4.34 M -15.8 M -

Revenue

 - - 323 K 1.76 M 1.92 M - 1.94 M 3.29 M 2.35 M - 1.53 M 1.72 M 1.41 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 143 K 71.7 K 160 K - 250 K - -

Cost of Revenue

 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 850 6.45 K 229 K - 254 K - -

Gross Profit

 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 142 K 65.2 K -69 K - -3.61 K - -

Operating Income

 -6.68 M -8.11 M -8.04 M -6.62 M -5.3 M - -5.4 M -3 M -2.59 M - -2.68 M -1.23 M -1.43 M - -904 K -4.25 M -4.55 M - -12.7 M -3.83 M -4.68 M - -5.27 M -3.66 M 2.96 M - -3.05 M -2.62 M -2.92 M - -6.97 M -3.08 M -3.35 M - -3.35 M -2.98 M -2.57 M - -5.8 M -3.8 M -6.22 M - -1.35 M -1.3 M -1.19 M - -3.51 M -1.8 M -1.37 M - -1.66 M -8.1 M -2.09 M - -3.43 M -3.43 M -2.35 M - -4.14 M -2.06 M -

Interest Expense

 2 K -1.02 K -1.23 K -10.3 K -135 - -3.44 K -247 -30 - 4.78 M -212 K 857 K - -88 - - - - - - - - - - - - - - - - - - - - 18.9 K 55.7 K - 1.38 K 6.22 K 21 - 76.2 K 33.3 K 50.8 K - 86.7 K 137 K 58.3 K - 13.4 K 35.1 K -23 K - - -52.3 K - - - - -

EBITDA

 -6.68 M -8.11 M - - -5.3 M - - - - - - - - - -904 K -4.25 M -4.55 M - -12.6 M -3.78 M -4.66 M - -5.2 M -3.6 M 2.98 M - -2.98 M -2.57 M -2.9 M - -6.89 M -3.02 M -3.32 M - -3.31 M -2.97 M -2.56 M - -5.78 M -3.8 M -6.22 M - -1.34 M -1.29 M -1.19 M - -3.14 M -1.48 M -1.18 M - -1.66 M -8.09 M -2.08 M - -3.42 M -3.42 M -2.34 M - -4.12 M -2.04 M -

Operating Expenses

 6.68 M 8.11 M 8.37 M 8.37 M 7.22 M - 7.34 M 6.28 M 4.94 M - 4.2 M 2.95 M 2.83 M - 904 K - - - - - - - - - - - - - - - - - - - - - - - - - - - 13.2 M 3.97 M 3.52 M - 3.51 M 1.8 M 1.37 M - 1.66 M 8.1 M 2.09 M - 3.57 M 2.51 M 2.28 M - 4.14 M 2.06 M -

General and Administrative Expenses

 2.36 M 2.98 M 2.33 M 3.27 M 2.38 M - 2.21 M 2.51 M 2.13 M - 2.41 M 993 K 1 M - 574 K 2.14 M 2.13 M - 1.93 M 1.84 M 1.74 M - 2.11 M 1.46 M 1.39 M - 1.29 M 1.07 M 1.2 M - 1.59 M 1.66 M 1.5 M - 1.56 M 1.8 M 1.55 M - 3.85 M 2.35 M 3.86 M - 422 K 347 K 459 K - 1.87 M 1.21 M 1.01 M - 449 K 514 K 625 K - 1.06 M 1.06 M 1.46 M - 2.55 M 1.12 M -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Diffusion Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Cellectar Biosciences Cellectar Biosciences
CLRB
 		$ 1.14 0.84 % $ 2.97 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
 		$ 11.32 0.17 % $ 4.7 B irlandaIrlanda
Alpine Immune Sciences Alpine Immune Sciences
ALPN
 		- - $ 2.17 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
 		- - $ 26.5 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
 		$ 1.02 0.49 % $ 11.5 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
 		$ 3.28 3.25 % $ 402 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
 		$ 23.19 0.04 % $ 734 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
 		$ 4.52 4.39 % $ 60.2 M usaUSA
Curis Curis
CRIS
 		$ 0.41 1.4 % $ 5.4 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
 		$ 9.52 5.01 % $ 752 M usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
 		- -8.77 % $ 12.4 M israelIsrael
Berkeley Lights Berkeley Lights
BLI
 		- -7.31 % $ 87 M usaUSA
Histogen Histogen
HSTO
 		- 31.6 % $ 2.12 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
 		$ 24.02 0.39 % $ 3.64 B usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
 		$ 17.61 2.63 % $ 3.04 B usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
 		$ 6.38 0.79 % $ 278 M usaUSA
ImmunoGen ImmunoGen
IMGN
 		- - $ 7.92 B usaUSA
Precision BioSciences Precision BioSciences
DTIL
 		$ 5.77 2.32 % $ 74 M usaUSA
Editas Medicine Editas Medicine
EDIT
 		$ 2.35 7.49 % $ 209 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
 		$ 84.95 0.13 % $ 7.99 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
 		$ 31.32 4.36 % $ 1.82 B usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
 		$ 11.1 2.59 % $ 237 K usaUSA
Exelixis Exelixis
EXEL
 		$ 62.23 0.06 % $ 16.9 B usaUSA
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
 		$ 2.99 4.32 % $ 219 K usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
 		$ 0.17 1.53 % $ 275 K usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
 		- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
 		- - $ 591 K irlandaIrlanda
Akebia Therapeutics Akebia Therapeutics
AKBA
 		$ 0.67 0.14 % $ 172 M usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
 		$ 49.51 1.0 % $ 201 B britainBritain
GT Biopharma GT Biopharma
GTBP
 		$ 7.03 18.52 % $ 38.8 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
 		$ 0.36 4.01 % $ 60 M usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
 		$ 255.56 0.86 % $ 615 B usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
 		$ 8.18 19.02 % $ 551 B britainBritain
Clovis Oncology Clovis Oncology
CLVS
 		- -7.23 % $ 13 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
 		$ 28.82 10.19 % $ 3.67 B usaUSA
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
 		$ 0.7 0.62 % $ 42 M usaUSA
Kura Oncology Kura Oncology
KURA
 		$ 9.08 0.94 % $ 796 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
 		- - $ 401 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
 		- - $ 231 M usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
 		- -3.69 % $ 12.4 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
 		$ 34.99 3.77 % $ 147 M usaUSA
Alector Alector
ALEC
 		$ 1.84 6.02 % $ 190 M usaUSA
ObsEva SA ObsEva SA
OBSV
 		- -15.52 % $ 10.5 M schweizSchweiz
Kronos Bio Kronos Bio
KRON
 		- 1.49 % $ 50.8 M usaUSA
Landos Biopharma Landos Biopharma
LABP
 		- 0.58 % $ 144 M usaUSA
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
 		- 7.4 % $ 6.29 M usaUSA
Provention Bio Provention Bio
PRVB
 		- - $ 2.37 B usaUSA
Poseida Therapeutics Poseida Therapeutics
PSTX
 		- - $ 857 M usaUSA
PolarityTE PolarityTE
PTE
 		- -0.82 % $ 1.78 M usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
 		- - $ 6.29 B usaUSA